CD8A and neoplasm: We leveraged the model to investigate potential sources of variability in anti-PD-(L)1 mediated anti-tumor response and identified PD-(L)1 receptor expression, CD8+ T cell half-life, CTL-mediated tumor cell killing rate, and maximum rate of CD8+ T cell influx into the tumor microenvironment as having substantial impact on anti-tumor response.